Article metrics

  • citations in SCindeks: 0
  • citations in CrossRef:0
  • citations in Google Scholar:[=>]
  • visits in previous 30 days:12
  • full-text downloads in 30 days:11
article: 3 from 6  
Back back to result list
Scripta Medica
2016, vol. 47, iss. 1, pp. 54-57
article language: Serbian
document type: Original Scientific Paper

Hemorrhagic complications of thrombolytic therapy eight years of experience from Banjaluka’s University hospital: Stroke unit
aClinic of Neurology, University Hospital Clinical Centre, Banja Luka, Republic of Srpska, Bosnia and Herzegovina
bInstitute of Pathology, University Hospital Clinical Centre, Banja Luka, Republic of Srpska, Bosnia and Herzegovina



Introduction. Intravenous thrombolysis with recombinant plasminogen activator is proven to be beneficial for patients with ischaemic stroke. Intracerebral hemorrhage represents the most serious complication of the treatment mentioned. Aim of this study. The aim of this retrospective study is a detailed analysis of intracranial hemorrhagic complications treated with recombinanttissue plasminogen activator. Patients and Methods. All intracerebral hemorrhage patients were classified according to the European Cooperative Acute Stroke Studyprotocol recommendations. A total of 188 patients were treated with thrombolytic therapy. Overall incidence of hemorrhagic complications was 22.3%, while the frequency of intracranial hemorrhagic events was 17%. The incidence of symptomatic intracranial hemorrhage was recorded in 6.9%, and the percentage of deaths after thrombolysis was in 5.3% of patients. Conclusion. The most common cause of deterioration in patients treated with recombinantt issue plasminogen activator is the occurrence of parenchymal hematoma type 2.Other forms of intracerebral hemorrhage after thrombolysis did not lead to clinical deteriorations. If existing recommendations are followed, thrombolytic therapy is safe.



*** (1995) Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N. Engl. J. Med., 333(24): 1581-7
Derex, L., Nighoghossian, N. (2008) Intracerebral haemorrhage after thrombolysis for acute ischaemic stroke: an update. J. Neurol. Neurosurg. Psychiatr., 79(10): 1093-9
European Stroke Initiative Executive Committee, EUSI Writing Committee, Olsen, T.S., Langhorne, P., Diener, H.C., Hennerici, M., Ferro, J., Sivenius, J., i dr. (2003) European stroke initiative recommendations for stroke management: Update 2003. Cerebrovasc Dis, 16 (4) 311- 337
Fonarow, G., Zhao, X., Smith, E., Saver, J., Reeves, M., Bhatt, D., i dr. (2014) Door-to-needle times for tissue plasminogen activator administration and clinical outcomes in acute ischemic stroke before and after a quality improvement initiative. JAMA, 311(16), 1632-1640
Hacke, W., Kaste, M., Bluhmki, E., Brozman, M., Davalos, A., Guidetti, D., i dr. (2008) Thrombolysis with alteplase 3 to 4. 5 hours after acute ischae mic stroke. N Engl J Med, 359, 1317-29
Molina, C.A., Alvarez-Sabín, J., Montaner, J., Abilleira, S., Arenillas, J.F., Coscojuela, P., Romero, F., Codina, A. (2002) Thrombolysis-related hemorrhagic infarction: a marker of early reperfusion, reduced infarct size, and improved outcome in patients with proximal middle cerebral artery occlusion. Stroke, 33(6): 1551-6
Rivera-Bou, W. Thrombolytic therapy for acute ischaemic stroke.
Tanne, D., Kasner, S.E., Demchuk, A.M., Koren-Morag, N., Hanson, S., Grond, M., Levine, S.R. (2002) Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: the Multicenter rt-PA Stroke Survey. Circulation, 105(14): 1679-85
Vujković, Z., Račić, D., Miljković, S., Đajić, V. (2012) Hemorrhagic complications of thrombolytic therapy. Medicinski pregled, vol. 65, br. 1-2, str. 9-12
WHO The top 10 causes of death
World Health Organization Global burden of stroke. in: The Atlas of Heart Disease and Stroke,